On January 23rd, CureX announced that it will use 20% of the sales revenue from its TRC-T product for the treatment of malignant synovial sarcoma to repurchase and destroy CUX tokens. This operation signifies CureX's further strengthening of the value and market stability of CUX tokens while promoting the application of its biotechnology products. In the first round of repurchase, CureX purchased 100 SOL and destroyed 4259993 CUX tokens. CureX promises to continue to use a portion of its product revenue for repurchasing and destroying CUX tokens in the future. CureX will continue to develop advanced biotechnology products to solve more medical problems and bring innovation to the global healthcare industry through innovative blockchain technology. At the same time, CureX airdrops to project 142pact, bringing a new cooperation experience.
All Comments